Synthesis of TRIOZAN-Peptide Conjugates as Blood-Brain Transient Drug Nanovector

作为血脑瞬时药物纳米载体的 TRIOZAN-肽缀合物的合成

• 批准号: 511143-2017
• 负责人: Dory, Yves
• 金额: $ 1.82万
• 依托单位: Université de Sherbrooke
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=639655
• 关键词: Synthesis; TRIOZAN; Peptide; Conjugates; Blood

In spite of considerable advancement in cancer chemotherapy, the survival rate in brain cancer patients isextremely limited mainly due to the blood-brain barrier (BBB) which prevents the transmission of drug fromblood circulation into the brain parenchyma. The present research proposal is based on the conjugation ofTRIOZANTM, as a nanomedicine delivery platform under proprietary of Ovensa Inc., with B1R agonist ligand.The permeability of B1R-functionalized TRIOZANTM will be evaluated via the measurement of its bindingaffinity to the endothelial cell receptors. Developed technology will be transferred to Ovensa Inc. as a key stepin developing of blood-brain-transient drug delivery platform.

尽管癌症化疗取得了相当大的进步，但脑癌患者的生存率极其有限，主要原因是血脑屏障（BBB）阻止药物从血液循环传播到脑实质。目前的研究计划是基于triozantm的偶联，作为Ovensa公司专有的纳米药物递送平台，与B1R激动剂配体。b1r功能化TRIOZANTM的通透性将通过测量其与内皮细胞受体的结合亲和力来评估。已开发的技术将转让给Ovensa公司，作为开发血脑瞬时给药平台的关键一步。